These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18710362)

  • 21. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
    Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
    Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of acute hereditary angioedema attacks with self-administered icatibant in patients with venous access problems.
    Wiednig M
    BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23625675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
    Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
    J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Icatibant in hereditary angioedema: news and challenges.
    Bouillet L
    Expert Rev Clin Immunol; 2011 May; 7(3):267-72. PubMed ID: 21595592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
    Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
    Krause K; Metz M; Zuberbier T; Maurer M; Magerl M
    J Dtsch Dermatol Ges; 2010 Apr; 8(4):272-4. PubMed ID: 19758369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
    Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
    Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
    Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
    Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In brief: icatibant (Firazyr) for hereditary angioedema.
    Medical Letter
    Med Lett Drugs Ther; 2011 Nov; 53(1378):96. PubMed ID: 22113125
    [No Abstract]   [Full Text] [Related]  

  • 31. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
    Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.
    Caballero T; Maurer M; Longhurst HJ; Aberer W; Bouillet L; Fabien V;
    J Investig Allergol Clin Immunol; 2016; 26(6):383-386. PubMed ID: 27996949
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
    Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
    Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
    Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Home treatment of hereditary angioedema with icatibant administered by health care professionals.
    Farkas H; Csuka D; Zotter Z; Varga L; Böröcz Z; Temesszentandrási G; Jakab L; Karádi I
    J Allergy Clin Immunol; 2012 Mar; 129(3):851-852.e2. PubMed ID: 22154383
    [No Abstract]   [Full Text] [Related]  

  • 37. [Allergy-immunology. New therapies for acute attacks in hereditary angioedema].
    Leimgruber A
    Rev Med Suisse; 2011 Jan; 7(278):103-5. PubMed ID: 21400938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic agents for hereditary angioedema.
    Giavina-Bianchi P; Motta A; Kalil J
    N Engl J Med; 2011 Jan; 364(1):85; author reply 86. PubMed ID: 21208116
    [No Abstract]   [Full Text] [Related]  

  • 39. Hereditary angioedema--therapies old and new.
    Morgan BP
    N Engl J Med; 2010 Aug; 363(6):581-3. PubMed ID: 20818894
    [No Abstract]   [Full Text] [Related]  

  • 40. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema.
    Drake D
    Emerg Med J; 2011 Aug; 28(8):720-1. PubMed ID: 21788245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.